UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 26, 2004
ARENA PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
DELAWARE |
|
000-31161 |
|
23-2908305 |
|
(State or Other Jurisdiction |
|
(Commission File Number) |
|
(I.R.S. Employer |
|
of Incorporation) |
|
|
|
Identification No.) |
6166 Nancy Ridge Drive, San Diego, California 92121
(Address of Principal Executive Offices) (Zip Code)
(858) 453-7200
(Registrant’s telephone number, including area code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events.
On October 26, 2004, Arena Pharmaceuticals, Inc. issued a press release announcing that Arena has achieved a pre-clinical development milestone under their collaboration with Merck & Co., Inc., a New Jersey corporation, as a result of Merck selecting an Arena-discovered compound for advancement in pre-clinical development. The milestone achievement triggered a $1 million payment to Arena. A copy of the press release is filed as Exhibit 99.1 hereto and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
|
(c) |
Exhibits. |
|
|
|
|
|
|
|
99.1 |
Press release issued October 26, 2004, announcing that Arena has achieved a pre-clinical development milestone under their collaboration with Merck as a result of Merck selecting an Arena-discovered compound for advancement in pre-clinical development. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Date: October 26, 2004 |
|
Arena Pharmaceuticals, Inc., |
||
|
|
|
a Delaware corporation |
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
By: |
/s/ Jack Lief |
|
|
|
|
|
Jack Lief |
|
|
|
|
|
President & Chief Executive Officer |
|
2
EXHIBIT INDEX
|
|
Description |
|
|
|
|
|
|
99.1 |
|
Press release issued October 26, 2004, announcing that Arena has achieved a pre-clinical development milestone under their collaboration with Merck as a result of Merck selecting an Arena-discovered compound for advancement in pre-clinical development. |
3